AIMS: The anti-anginal efficacy and safety of ranolazine in diabetic and non-diabetic patients included in the Combination Assessment of Ranolazine In Stable Angina (CARISA) trial (JAMA 2004;291:309) were studied. Glycaemic control was also assessed in CARISA and its long-term open-label extension study. METHODS AND RESULTS:Patients with chronic angina enrolled in CARISA (189 with diabetes, 634 without diabetes) on background atenolol, diltiazem, or amlodipine therapy were randomized to placebo, ranolazine 750 or 1000 mg twice daily for 12 weeks, during which exercise tolerance, angina frequency, nitroglycerin usage, glucose, HbA(1c), and lipids were measured. Patients completing the randomized study could enroll in an ongoing open-label extension study and were evaluated every 3 months. Ranolazine produced similar improvements in exercise parameters, nitroglycerin use, and angina frequency in diabetic and non-diabetic patients. Adverse events were similar between groups. Fasting glucose and lipids remained unaltered in diabetic patients after 12 weeks of therapy. In a post hoc analysis, ranolazine 750 and 1000 mg reduced HbA(1c) vs. placebo by 0.48+/-0.18% (P=0.008) and 0.70+/-0.18% (P=0.0002), respectively; the HbA(1c) levels appeared to remain unchanged over time during long-term therapy. CONCLUSION: Anti-anginal efficacy and safety of ranolazine for angina were similar between diabetic and non-diabetic patients. Ranolazine significantly improved glycaemic control in diabetic patients.
RCT Entities:
AIMS: The anti-anginal efficacy and safety of ranolazine in diabetic and non-diabeticpatients included in the Combination Assessment of Ranolazine In Stable Angina (CARISA) trial (JAMA 2004;291:309) were studied. Glycaemic control was also assessed in CARISA and its long-term open-label extension study. METHODS AND RESULTS:Patients with chronic angina enrolled in CARISA (189 with diabetes, 634 without diabetes) on background atenolol, diltiazem, or amlodipine therapy were randomized to placebo, ranolazine 750 or 1000 mg twice daily for 12 weeks, during which exercise tolerance, angina frequency, nitroglycerin usage, glucose, HbA(1c), and lipids were measured. Patients completing the randomized study could enroll in an ongoing open-label extension study and were evaluated every 3 months. Ranolazine produced similar improvements in exercise parameters, nitroglycerin use, and angina frequency in diabetic and non-diabeticpatients. Adverse events were similar between groups. Fasting glucose and lipids remained unaltered in diabeticpatients after 12 weeks of therapy. In a post hoc analysis, ranolazine 750 and 1000 mg reduced HbA(1c) vs. placebo by 0.48+/-0.18% (P=0.008) and 0.70+/-0.18% (P=0.0002), respectively; the HbA(1c) levels appeared to remain unchanged over time during long-term therapy. CONCLUSION: Anti-anginal efficacy and safety of ranolazine for angina were similar between diabetic and non-diabeticpatients. Ranolazine significantly improved glycaemic control in diabeticpatients.
Authors: Alexander C Fanaroff; Stefan K James; Giora Weisz; Kristi Prather; Kevin J Anstrom; Daniel B Mark; Ori Ben-Yehuda; Karen P Alexander; Gregg W Stone; E Magnus Ohman Journal: J Am Coll Cardiol Date: 2017-05-09 Impact factor: 24.094
Authors: Jeffrey W Chisholm; Allison B Goldfine; Arvinder K Dhalla; Eugene Braunwald; David A Morrow; Ewa Karwatowska-Prokopczuk; Luiz Belardinelli Journal: Diabetes Care Date: 2010-03-31 Impact factor: 17.152
Authors: U J Roblick; D Hirschberg; J K Habermann; C Palmberg; S Becker; S Krüger; M Gustafsson; H-P Bruch; B Franzén; T Ried; T Bergmann; G Auer; H Jörnvall Journal: Cell Mol Life Sci Date: 2004-05 Impact factor: 9.261